PET/CT with F-18 FDG 

 

REASON FOR EXAM:     

 

HISTORY:     

 

COMPARISON STUDIES:     

 

SERUM GLUCOSE LEVEL:     mg/dL 

 

RADIOPHARMACEUTICAL: F-18 FDG     mCi 

 

CTDI:      mGy 

 

DLP:      mGy-cm 

 

TECHNIQUE: The study was performed using in-line PET/CT from the skull vertex to the mid-thigh. Cross-sectional as well as 3D (MIP) images of the PET data and cross-sectional images of the CT data were generated with co-registration of the 2 image sets. The PET images are displayed with and without  attenuation correction.  CT imaging was employed for attenuation correction and anatomic localization of PET scan abnormalities.   

 

FINDINGS: 

Head and neck:  

Normal FDG uptake is seen throughout the brain. High physiologic FDG uptake throughout the cortical gray matter limits the sensitivity of PET for evaluation of the brain. 

 

No suspicious hypermetabolic lesion or lymph node identified within the head and neck. The thyroid gland is grossly normal in appearance. 

 

Chest: 

No suspicious hypermetabolic pulmonary nodule identified. No suspicious hypermetabolic mediastinal, hilar, internal mammary, or axillary lymph node identified. No appreciable coronary artery calcification. 

 

Abdomen and pelvis: 

No suspicious hypermetabolic lesion identified within the abdomen and pelvis. No suspicious hypermetabolic abdominal, pelvic, or inguinal lymph node identified. 

 

Heterogenous radiotracer activity pattern within the GI tract is within normal. Physiologic FDG activity is seen bilaterally in the kidneys and in the urinary bladder secondary to normal route of radiotracer excretion. 

 

Musculoskeletal/Body wall:  

No suspicious focal hypermetabolic osseous lesion identified. No significant sclerotic or lytic osseous lesion identified. No acute or aggressive osseous lesion. No suspicious hypermetabolic body wall soft tissue lesion identified. 

 

IMPRESSION: